882 results match your criteria Expert Review of Hematology [Journal]


Developments in diagnosis and treatment of essential thrombocythemia.

Expert Rev Hematol 2019 Feb 22. Epub 2019 Feb 22.

b Universita degli Studi dell'Insubria , Varese 21100 , Italy.

Introduction: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by thrombocytosis, increased risk of thrombotic/hemorrhagic events and clonal evolution into blast phase or myelofibrosis. Areas Covered: The authors will discuss biology, diagnosis, prognosis, therapy and outcome of ET. An accurate molecular-morphologic assessment is necessary in order to properly establish diagnosis and prognosis of ET. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1585239DOI Listing
February 2019

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor T-cell therapy.

Expert Rev Hematol 2019 Feb 22. Epub 2019 Feb 22.

a Division of Medical Oncology, Department of Internal Medicine , University of Washington School of Medicine , Seattle , WA , USA.

Introduction: Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated remarkable anti-tumor activity in B-cell malignancies and is under investigation in other hematologic malignancies and solid tumors. While highly efficacious, post-infusion T cell activity often results in massive cytokine release precipitating cytokine release syndrome (CRS), the signature toxicity of CAR T cells. This toxicity is characterized by systemic immune activation resulting in fever, hypotension, respiratory insufficiency and capillary leak. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1585238DOI Listing
February 2019

New directions in treating peripheral T-cell lymphomas (ptcl): leveraging epigenetic modifiers alone and in combination.

Expert Rev Hematol 2019 Feb 20. Epub 2019 Feb 20.

a Center for Lymphoid Malignancies, Division of Hematology and Oncology, Department of Medicine , Columbia University Medical Center, College of Physicians and Surgeons , New York , N.Y. , USA.

Introduction: The peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of non-Hodgkin lymphomas originating from mature T- and NK-cells. They are aggressive diseases often resistant to chemotherapy. Areas Covered: The methodology of this review involves a literature search of data published on PubMed, abstracts from international conferences, and our own research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583102DOI Listing
February 2019

BRAF in the cross-hairs.

Expert Rev Hematol 2019 Feb 20. Epub 2019 Feb 20.

a Leukemia Service , Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center , New York , NY , 10065 , USA.

Introduction: Hairy cell leukemia (HCL) is a rare, chronic B-cell lymphoproliferative disorder characterized by distinctive morphologic features and an indolent clinical course. The discovery of a recurrent activating mutation in BRAF (BRAF V600E) as a disease-defining genetic event in HCL has substantial diagnostic and therapeutic implications. Areas covered: Herein the authors review the role of BRAF V600E and RAF-MEK-ERK signaling in the pathogenesis of HCL, anecdotal clinical reports of BRAF inhibitor monotherapy in management of relapsed or refractory HCL, larger phase 2 trials investigating efficacy of BRAF inhibitor therapy for HCL, adverse effects commonly associated with BRAF inhibitor therapy, including cutaneous toxicity, and mechanisms of therapeutic resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583553DOI Listing
February 2019

Thrombophilia, risk factors and prevention.

Expert Rev Hematol 2019 Feb 18. Epub 2019 Feb 18.

a Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine (DIMED), Padova University Hospital , Italy.

Introduction: Fifty-three years after the first description of an inherited prothrombotic condition (antithrombin deficiency), our knowledge on hereditary and acquired causes of hypercoagulability that can predispose carriers to venous thromboembolism (VTE) has greatly improved. Areas covered: Main causes of hereditary thrombophilia are summarized alongside new prothrombotic mutations recently discovered. The main causes of acquired thrombophilia, and namely, antiphospholipid antibody syndrome and hyperhomocysteinemia, are also discussed together with other common acquired prothrombotic states characterized by an increase of procoagulant factors and/or a decrease of natural anticoagulants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583555DOI Listing
February 2019
1 Read

Overcoming challenges of venous thromboembolism in sickle cell disease treatment.

Expert Rev Hematol 2019 Feb 16. Epub 2019 Feb 16.

a Johns Hopkins School of Medicine , Baltimore , MD , USA.

Introduction: Venous thromboembolism (VTE) is a common comorbid condition found in sickle cell disease (SCD) and is associated with increased mortality for adults with SCD. The pathophysiology that leads to the thrombophilic state in SCD has been previously reviewed; however, evidence-based guidelines to aid in diagnosis, prevention and management of VTE are lacking. Areas covered: This review article will cover the pathophysiology underlying the hypercoagulable state, the epidemiology of VTE, and management strategies of VTE in SCD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583554DOI Listing
February 2019

Risk adapted Post-Transplant Maintenance in Multiple Myeloma.

Expert Rev Hematol 2019 Jan 29. Epub 2019 Jan 29.

a Division of Hematology , Mayo Clinic , Rochester , MN , USA .

Introduction: The survival of multiple myeloma patients is increasing due to new medications, the widespread implementation of autologous stem cell transplantation and better supportive treatments. The controversy surrounding post-transplant treatment is debated due to a lack of large randomized trials comparing the different treatment modalities. The questions for each proposed treatment are whether it improves outcomes, has low cumulative toxicities and is easy to administer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1576521DOI Listing
January 2019
2 Reads

A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.

Expert Rev Hematol 2019 Jan 28:1-8. Epub 2019 Jan 28.

b International Market Access , Pharmacosmos A/S , Holbæk , Denmark.

Objectives: The efficacy of oral iron in treating iron deficiency anemia (IDA) can be limited by poor gastrointestinal (GI) absorption and adverse GI symptoms; intravenous (IV) iron is a well-established alternative. The present study compared the efficacy of two IV iron formulations in patients with IDA: iron isomaltoside (IIM) and ferric carboxymaltose (FCM).

Methods: A systematic literature review (SLR) was conducted to identify randomized controlled trials (RCTs) of IIM and FCM in patients with IDA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1575202DOI Listing
January 2019

Thrombotic complications in adult patients with severe single coagulation factor or platelet defects - an overview.

Expert Rev Hematol 2019 Jan 28:1-10. Epub 2019 Jan 28.

a Section for Hematology, Department of Clinical Science , University of Bergen , Bergen , Norway.

Introduction: Even though thrombotic events are rare in patients with coagulation deficiencies, several cases of both arterial and venous thromboses have been reported in patients with single coagulation factor defects and platelet defects. Thromboses have been described both in hemophilia A and B, von Willebrand disease as well as in many other rare congenital coagulation factor and platelet defects. Thromboses may also occur in patients with acquired hemophilia and in patients with severe thrombocytopenia due to hematological malignancies or intensive chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1570126DOI Listing
January 2019
4 Reads

Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment.

Expert Rev Hematol 2019 Feb 6:1-10. Epub 2019 Feb 6.

a Division of Hematology, Oncology Institute of Southern Switzerland and Laboratory of Experimental Hematology , Institute of Oncology Research , Bellinzona , Switzerland.

Introduction: Several recurrently deregulated pathways implicated in the development of chronic lymphocytic leukemia (CLL) have been described over the last decades. Knowledge of the CLL genetic heterogeneity led to the definition of molecular biomarkers informing about prognosis and treatment outcome. Areas covered: English literature published from January 2008 through December 2018 was searched in PubMed, Cochrane Central Register of Controlled Trials, and hematology meeting abstracts to obtain literature on clinical predictive factors for CLL. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1575130DOI Listing
February 2019
2 Reads

Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions.

Expert Rev Hematol 2019 Jan 11:1-8. Epub 2019 Jan 11.

b Department of Internal Medicine, Division of Blood and Marrow Transplantation , Stanford University School of Medicine , Stanford , CA , USA.

Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) has seen marked growth among older adults, where chronological age is no longer a barrier to transplant. As allo-HCT expands to older and potentially less fit individuals, prognosticating transplant outcomes in this population remains an ongoing need. Areas covered: This review summarizes pre-transplant assessment tools in optimizing patient selection and predicting transplant outcomes in older adults, including comorbidity indices, psychosocial assessment, geriatric assessment, serum biomarkers, and disease risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1568236DOI Listing
January 2019
1 Read

Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis.

Expert Rev Hematol 2019 Jan 29;12(1):47-60. Epub 2018 Dec 29.

a Stem Cell Transplant Program, University Hospitals Cleveland Medical Center , Case Western Reserve University , Cleveland , OH , USA.

Introduction: Allogeneic hematopoietic cell transplantation is frequently used to treat malignant and non-malignant conditions, and many patients lack a human leukocyte antigen (HLA) matched related or unrelated donor. For those patients, available alternative graft sources include HLA mismatched unrelated donors, cord blood, or haplo-identical donors. These graft sources have unique characteristics and associated outcomes requiring graft-specific variations to conditioning regimens, graft-versus-host disease prophylaxis, and post-transplant care. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1562331DOI Listing
January 2019
6 Reads

Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors.

Expert Rev Hematol 2019 Jan 28;12(1):21-28. Epub 2019 Jan 28.

a Haemophilia Treatment Centre , University Hospital Montpellier , Montpellier , France.

Introduction: Hemophilia A and B are X-linked recessive disorders caused by the deficiency of factor VIII or factor IX, respectively. Bleeding episodes are treated with factor replacement therapy. The most serious complication of this treatment is the development of inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1560259DOI Listing
January 2019
3 Reads

Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.

Expert Rev Hematol 2018 Dec 20. Epub 2018 Dec 20.

a Hematology, Department of Cellular Biotechnologies and Hematology , Policlinico Umberto 1, 'Sapienza' University , Rome , Italy.

Introduction: The outcome of acute promyelocytic leukemia (APL) has drastically improved following the identification of the PML-RARA oncogene as a key player in the pathogenesis of APL, and the subsequent introduction of all-trans retinoic acid (ATRA) as a therapeutic agent. Areas covered: Randomized trials have recently demonstrated the efficacy of arsenic trioxide (ATO) in combination with ATRA for the front-line treatment of standard and medium risk APL patients. This chemotherapy-free combination is associated with a decreased cumulative rate of relapse, prolonged overall survival and reduced early death rate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1562332DOI Listing
December 2018
1 Read

Platelet function assays in diagnosis: an update.

Expert Rev Hematol 2019 Jan 16;12(1):29-46. Epub 2019 Jan 16.

a Department of Medicine, Section of Internal and Cardiovascular Medicine , University of Perugia , Perugia , Italy.

Introduction: Hemorrhagic diseases associated with platelet dysfunction include inherited platelet function disorders (IPFD) and a large number of non-hereditary conditions, defined as acquired platelet function disorders (APFD). Their identification requires a careful clinical evaluation and a rational use of diagnostic laboratory assays. Areas covered: Here we describe the laboratory techniques currently available for the assessment of platelet function, including new and experimental laboratory assays, and their alterations in platelet function disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1562333DOI Listing
January 2019
1 Read

Brentuximab vedotin in T-cell lymphoma.

Expert Rev Hematol 2019 Jan 18;12(1):5-19. Epub 2018 Dec 18.

a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Australia.

Introduction: Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. The utility of brentuximab vedotin has been explored in a number of diseases, with a recent focus on T-cell lymphoma, particularly systemic anaplastic large-cell lymphoma (sALCL) and cutaneous T-cell lymphoma (CTCL), as well as other peripheral T-cell lymphoma (PTCL) histologies. Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-cell lymphoma, as well as embedding it in a therapeutic context by reviewing potential competitor agents in the clinic. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1558399DOI Listing
January 2019
12 Reads

Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.

Expert Rev Hematol 2019 Jan 12;12(1):71-79. Epub 2018 Dec 12.

c Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , Cambridge , UK.

Background: Immunomodulator (IMID) and proteasome inhibitor (PI) triplet frontline therapy (FT) in newly diagnosed multiple myeloma (NDMM) trials improve overall survival (OS); reported outcomes in routine practice are lacking. Authors compared outcomes in NDMM patients in the USA by use of triplet vs doublet FTs.

Methods: In this retrospective study of NDMM patients without FT transplant between 1/1/2008 and 6/30/2017, FT was categorized as: PI+IMID-triplet (≥ 3 drugs including PI+IMID), non-PI+IMID-triplet (≥ 3 drugs, not PI+IMID), doublet (≤ 2 drugs). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1555460DOI Listing
January 2019
16 Reads

Measurable residual disease in acute myeloid leukemia using flowcytometry: approaches for harmonization/standardization.

Expert Rev Hematol 2018 Nov 23. Epub 2018 Nov 23.

a Department of Hematology , VU University Medical Center , De Boelelaan 1117, 1081 HV Amsterdam , Netherlands.

Introduction: Measurable Residual Disease (MRD) in acute myeloid leukemia (AML) is a rapidly evolving area with many institutes embarking on it, both in academical and pharmaceutical settings. However, there is a multitude of approaches to design, perform and report flow cytometric MRD. Together with the long-term experience needed, this makes flow cytometric MRD in AML non-standardized and time-consuming. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1549479DOI Listing
November 2018
2 Reads

rFVIIIFC for hemophilia A prophylaxis.

Authors:
Johnny Mahlangu

Expert Rev Hematol 2018 Nov 19. Epub 2018 Nov 19.

a NHLS and the Charlotte Maxeke , Johannesburg academic Hospital, University of the Witwatersrand , Johannesburg , South Africa.

Introduction: rFVIIIFC was the first extended half-life product to complete the phase 3 development program and be registered. It was developed to reduce the high treatment burden imposed by prophylaxis. It is now one of four extended half-life products available for a variety of indications in hemophilia A. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1549478DOI Listing
November 2018
7 Reads

Health-related quality of life in adult primary immune thrombocytopenia.

Expert Rev Hematol 2018 Nov 16:1-11. Epub 2018 Nov 16.

a Depatment of Haematology , Odense University Hospital , Odense , Denmark.

Introduction: Immune thrombocytopenia (ITP) and the associated biologic and psychological effects can lead to reduced health-related quality of life (HRQoL). Areas covered: This review focuses on the impact of ITP itself and its treatment on patients' HRQoL. The findings show that the HRQoL is uniformly reduced amongst ITP patients, both with and without interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1548930DOI Listing
November 2018
10 Reads

Current strategies for hemostatic control in acute trauma hemorrhage and trauma-induced coagulopathy.

Expert Rev Hematol 2018 Nov 15:1-9. Epub 2018 Nov 15.

b Department of Traumatology and Orthopaedic Surgery, Cologne-Merheim Medical Centre (CMMC) , Witten/Herdecke University , Cologne , Germany.

Introduction: Despite advances in the treatment of severely injured patients that have resulted in overall improved outcomes, uncontrolled hemorrhage still represents the most common cause of preventable death following major injury. While addressing both endo- and exogenous factors that lead to an acute trauma-induced coagulopathy, massive transfusion plays a key role in managing bleeding trauma patients. However, the best practice for hemostatic control including massive transfusion in these patients is still under debate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1548929DOI Listing
November 2018
3 Reads

Venetoclax for the treatment of multiple myeloma.

Expert Rev Hematol 2018 Nov 14. Epub 2018 Nov 14.

a Division of Hematology , Mayo Clinic , Rochester , MN , USA.

Introduction: Treatment of multiple myeloma in the relapsed setting remains challenging, despite recent impressive advances in the management of these patients. Venetoclax (ABT-199) is a BCL-2 inhibitor recently approved by the US food and drug administration (FDA) for treatment of chronic lymphocytic leukemia but the drug has shown activity in a number of hematological malignancies. Venetoclax has broadened the treatment options for patients with relapsed or refractory multiple myeloma. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1548931DOI Listing
November 2018
16 Reads

Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia.

Expert Rev Hematol 2019 Jan 14;12(1):1-3. Epub 2018 Nov 14.

a Data Center and Health Outcomes Research Unit , Italian Group for Adult Hematologic Diseases (GIMEMA) , Rome , Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1547189DOI Listing
January 2019
3 Reads

Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.

Expert Rev Hematol 2018 Dec 8;11(12):945-956. Epub 2018 Nov 8.

a Department of Pediatric Hematology and Oncology , IRCCS, Ospedale Pediatrico Bambino Gesù , Rome , Italy.

Introduction: The clinical application of immunotherapy has resulted into a significant improvement in the outcome of children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL). In this setting, the use of bispecific T-cell-engager antibodies (BiTEs), such as blinatumomab, which harness the cytotoxic activity of T cells against CD19-positive lymphoblasts, has emerged as a most promising and impactful strategy. Areas covered: This review discusses the main structural and functional features of BiTEs, as well as the current status of their clinical application in childhood ALL. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1540928DOI Listing
December 2018
6 Reads

Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities.

Expert Rev Hematol 2018 Oct 19. Epub 2018 Oct 19.

c Division of Medical Oncology, Department of Medicine , University of Washington , Seattle , WA.

Introduction: Multiple three drug combination regimens have been approved for the treatment of multiple myeloma in the last few years. Triplets have become the new standard of care for transplant eligible and ineligible patients with newly diagnosed as well as relapsed multiple myeloma. Novel agents have a unique profile of side effects. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1538777DOI Listing
October 2018
21 Reads

Optimal frontline management of mantle cell lymphoma: can we agree?

Expert Rev Hematol 2018 Oct 19:1-4. Epub 2018 Oct 19.

a Division of Medical Oncology & Hematology , Princess Margaret Cancer Centre , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1537778DOI Listing
October 2018
2 Reads

An update on treatment of higher risk myelodysplastic syndromes.

Expert Rev Hematol 2019 Jan 18;12(1):61-70. Epub 2018 Dec 18.

a Service Hématologie Séniors, Hôpital Saint Louis , Université Paris Diderot, Assistance Publique-Hôpitaux de Paris , Paris , France.

Introduction: Myelodysplastic syndromes (MDS) are clonal stem cell disorders mostly affecting the elderly. They are classified into lower and higher risk MDS according to prognostic scoring systems. In higher risk patients, treatments should aim to modify the disease course by avoiding progression to acute myeloid leukemia and, therefore, to improve survival. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1537777DOI Listing
January 2019
8 Reads

Prognostic factors for multiple myeloma in the era of novel therapies.

Expert Rev Hematol 2018 Nov 26;11(11):863-879. Epub 2018 Oct 26.

a Department of Clinical Therapeutics, School of Medicine, "Alexandra" General Hospital , National and Kapodistrian University of Athens , Athens , Greece.

Introduction: Multiple myeloma (MM) is characterized by notable inter-patient and intra-clonal heterogeneity that is gradually decoded over the last decade. Despite the deeper and better understanding of its biology and the development of novel therapeutic strategies that have prolonged overall survival, MM still retains a poor prognosis in patient subgroups with certain high-risk features. Areas covered: This article summarizes currently identified features that stratified patients in high-risk myeloma with impaired prognosis and discusses available therapeutic options that may partially overcome the impact of these adverse factors in patients' outcome. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1537776DOI Listing
November 2018
19 Reads

Novel treatments to tackle myelofibrosis.

Expert Rev Hematol 2018 Nov 26;11(11):889-902. Epub 2018 Oct 26.

a Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , Myeloproliferative Neoplasms Research Program , New York , NY , USA.

Introduction: Despite the dramatic progress made in the treatment of patients with myelofibrosis since the introduction of the JAK1/2 inhibitor ruxolitinib, a therapeutic option that can modify the natural history of the disease and prevent evolution to blast-phase is still lacking. Recent investigational treatments including immunomodulatory drugs and histone deacetylase inhibitors benefit some patients but these effects have proven modest at best. Several novel agents do show promising activity in preclinical studies and early-phase clinical trials. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1536538DOI Listing
November 2018
33 Reads

Andexanet alfa for the treatment of hemorrhage.

Expert Rev Hematol 2018 Nov 17;11(11):847-855. Epub 2018 Oct 17.

b Department of Pathology and Molecular Medicine, Faculty of Health Sciences , McMaster University , Hamilton , Ontario , Canada.

Introduction: While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among clinicians. Andexanet alfa is a recombinant human factor Xa decoy protein developed in response to this clinical gap in the care of patients receiving anticoagulation with factor Xa inhibitors. Areas covered: This paper reviews results from preclinical and healthy-volunteer studies demonstrating the ability of andexanet to rapidly and reliably normalize coagulation indices in patients treated with both direct and indirect factor Xa inhibitors. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1532287DOI Listing
November 2018
4 Reads

The importance of inhibitor eradication in clinically complicated hemophilia A patients.

Expert Rev Hematol 2018 Nov 4;11(11):857-862. Epub 2018 Oct 4.

f Hemophilia Center Rhein-Main - HZRM , Frankfurt - Mörfelden , Germany.

Introduction: Inhibitors against factor VIII (FVIII), which develop in around 20-30% of patients with severe hemophilia A, represent a significant complication of on-demand or prophylactic FVIII therapy. Currently, the main treatment option for inhibitor patients is eradication using immune tolerance induction (ITI) therapy. Areas covered: This article reviews inhibitor eradication in clinically complicated hemophilia A patients. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1521718DOI Listing
November 2018
11 Reads

Management of multiple myeloma bone disease: impact of treatment on renal function.

Expert Rev Hematol 2018 Nov 20;11(11):881-888. Epub 2018 Oct 20.

a Department of Clinical Therapeutics , National and Kapodistrian University of Athens School of Medicine, Alexandra General Hospital , Athens , Greece.

Introduction: Bone disease (BD) is one of the most common features of multiple myeloma. Seventy to eighty percent of patients at diagnosis present with lytic lesions which may lead to skeletal-related events. Areas covered: The aim of this review is to present the possible adverse profile of bisphosphonates (BPs) on renal function, the underlying mechanisms by which BPs may affect renal function and the novel therapeutic approaches on myeloma bone disease management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1531702DOI Listing
November 2018
5 Reads

Emicizumab for hemophilia A with factor VIII inhibitors.

Expert Rev Hematol 2018 Nov 10;11(11):835-846. Epub 2018 Oct 10.

f Department of Pediatrics , University of Michigan , Ann Arbor , MI , USA.

Introduction: Hemophilia is a serious bleeding disorder characterized by repeated bleeding episodes into joints and muscles which can lead to permanent disabilities. Treatment with factor replacement therapy has proven to be effective at preventing these complications; however, it can lead to formation of neutralizing antibodies termed inhibitors which significantly complicate the management of the disorder. These inhibitor patients suffer from increased morbidity and mortality and there has been a major unmet need for novel therapeutic approaches. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1531701DOI Listing
November 2018
11 Reads

The prevention of venous thromboembolism recurrence in the elderly: a still open issue.

Expert Rev Hematol 2018 Nov 26;11(11):903-909. Epub 2018 Sep 26.

b Thrombosis Centre , Azienda Ospedaliero-Universitaria Careggi , Florence , Italy.

Introduction: Venous thromboembolism (VTE) is frequent in the elderly, with an unclear recurrence risk. After the initial and early maintenance anticoagulant treatment, the decision about its extension versus recurrences is difficult because of the high risk of bleeding in this population. Areas covered: This paper analyzes recent literature on VTE recurrence and risk of bleeding associated with extended anticoagulation in elderly patients with VTE, focusing on available data regarding efficacy and safety of old anticoagulant or recent direct oral anticoagulant (DOACs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1526667DOI Listing
November 2018
7 Reads

Ferumoxytol for the treatment of iron deficiency anemia.

Expert Rev Hematol 2018 Oct 14;11(10):829-834. Epub 2018 Sep 14.

c Department of Medicine , University of Virigina Health System , Charlottesville , Virignia , USA.

Introduction: Ferumoxytol is a superparamagnetic molecule originally developed as a contrast agent for magnetic resonance imaging. Elemental iron is contained within the carbohydrate core and is released slowly after infusion allowing a large dose of iron to be administered in a short period of time. Ferumoxytol, originally approved for iron deficiency in chronic kidney disease, received a broad label for any cause of iron deficiency after oral iron intolerance or in those circumstances when oral iron is ineffective or harmful. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1518712DOI Listing
October 2018
16 Reads

Ixazomib: a novel drug for multiple myeloma.

Expert Rev Hematol 2018 Oct;11(10):761-771

a Division of Hematology , Mayo Clinic , Rochester , MN , USA.

Introduction: Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1518129DOI Listing
October 2018
54 Reads

Anticoagulation at the extremes of body weight: choices and dosing.

Expert Rev Hematol 2018 Oct 25;11(10):817-828. Epub 2018 Sep 25.

d Department of Clinical Haematology , Westmead Hospital , Westmead , Australia.

Introduction: The landscape of therapeutic anticoagulation has changed dramatically over the past decade, with availability of direct oral anticoagulants (DOACs), which inhibit factor Xa or thrombin. However, the optimal anticoagulant agent and dosing strategy for patients at both extremes of body weight has not been established for any anticoagulant, including DOACs, vitamin K antagonists (VKA), and the various heparin options. Areas covered: This paper reviews available evidence to assist clinicians in prescribing of anticoagulation therapy at the extremes of body weight. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1517040DOI Listing
October 2018
34 Reads

The potential role of miRNAs in multiple myeloma therapy.

Expert Rev Hematol 2018 Oct 12;11(10):793-803. Epub 2018 Sep 12.

a Department of Experimental and Clinical Medicine , Magna Græcia University, Campus Salvatore Venuta , Catanzaro , Italy.

Introduction: MicroRNAs (miRNAs) are short non-coding RNAs that are crucial players as post-transcriptional regulators of messenger RNAs (mRNAs). miRNA deregulation has been associated to the pathogenesis of several human malignancies, since they might potentially regulate relevant pathways involved in cancer onset and progression. Therefore, targeting the miRNA network could represent a promising therapeutic strategy for human cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1517041DOI Listing
October 2018
2 Reads

Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma.

Expert Rev Hematol 2018 Oct 5;11(10):773-780. Epub 2018 Sep 5.

a Lombardi Comprehensive Cancer Center , MedStar Georgetown University Hospital , Washington , DC , USA.

Introduction: Hodgkin's lymphoma (HL) accounts for about 10% of all lymphomas in the U.S.A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1516135DOI Listing
October 2018
15 Reads

Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes.

Expert Rev Hematol 2018 Oct 16;11(10):805-816. Epub 2018 Aug 16.

a Clinical Research Division , Fred Hutchinson Cancer Research Center , Seattle , WA , USA.

Introduction: Allogeneic hematopoietic cell transplantation (HCT) provides potential cure to a large number of malignant and nonmalignant hematological disorders. With the development of non-myeloablative and reduced-intensity conditioning regimens, allogeneic HCT can nowadays be offered to a number of older or medically unfit patients. Up until the twenty-first century, chronological age was considered a hypothetical barrier. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1509703DOI Listing
October 2018
1 Read

Advances in the genetics of acute lymphoblastic leukemia in adults and the potential clinical implications.

Expert Rev Hematol 2018 Oct 16;11(10):781-791. Epub 2018 Aug 16.

a Department of Hematology and Bone Marrow Transplantation , Rambam Health Care Campus , Haifa , Israel.

Introduction: Acute lymphoblastic leukemia (ALL) is a clonal disease of the hematopoietic system characterized by unique genetic characteristics. The significance of these genetic features has evolved over the past three decades. In the 1980s and 1990s, the primary interest was in excluding the Philadelphia chromosome; a finding more common in older adults which uniformly predicted for a rapidly fatal outcome. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2018.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2018.1509702DOI Listing
October 2018
12 Reads

Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy.

Expert Rev Hematol 2018 Sep 14;11(9):697-706. Epub 2018 Aug 14.

a University Clinic for Haematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, UKRUB, University of Bochum , Minden , Germany.

Introduction: The management of pregnancy during the course of BCR-ABL1-negative myeloproliferative neoplasms (MPN) is an increasingly relevant problem. This is mostly due to earlier and better diagnosis of MPN together with the trend in modern society toward delaying pregnancy until later life. Areas Covered: The present review aims to provide an overview of the available literature data concerning outcome of pregnancy in MPN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1506325DOI Listing
September 2018
16 Reads

Non-Hodgkin's lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint.

Expert Rev Hematol 2018 Sep 21;11(9):737-748. Epub 2018 Aug 21.

a Department of Pathology , Assiut University Hospitals , Assiut , Egypt.

Introduction: Non-Hodgkin lymphomas of the oral and maxillofacial regions are uncommon malignancies. They usually have progressive course and dismal outcome. Areas covered: This review provides an update about the clinicopathologic, immunophenotypic, and molecular features of these lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1506326DOI Listing
September 2018
10 Reads

New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?

Expert Rev Hematol 2018 Sep 2;11(9):749-756. Epub 2018 Aug 2.

b Department of Hematology and Hematopoietic Cell Transplantation , City of Hope National Medical Center , Duarte , CA , USA.

Introduction: Despite recent prognostic improvements, mantle cell lymphoma (MCL) remains incurable. Bruton tyrosine kinase (BTK) is a key receptor in B-cell tumorigenesis, and the benefits of the first BTK inhibitor, ibrutinib, are becoming clear in MCL. However, off-target activities, which contribute to ibrutinib-related adverse events, suggest potential for further improvement of this drug class. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1506327DOI Listing
September 2018
3 Reads

Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.

Expert Rev Hematol 2018 Sep 22;11(9):715-726. Epub 2018 Aug 22.

a Division of Hematology/Medical Oncology, Department of Medicine , Yale University School of Medicine , New Haven , USA.

Introduction: Myelodysplastic syndromes (MDS) encompass a heterogenous collection of clonal hematopoietic stem cell disorders defined by dysregulated hematopoiesis, peripheral cytopenias, and a risk of leukemic progression. Increasing data support the role of innate and adaptive immune pathways in the pathogenesis and disease course of MDS. The role of immunosuppressive therapy has an established role in the treatment of other hematologic diseases, such as aplastic anemia whose pathogenesis is postulated to reflect that of MDS with regards to many aspects of immune activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1503049DOI Listing
September 2018
18 Reads

Impact and management of iron deficiency and iron deficiency anemia in women's health.

Expert Rev Hematol 2018 Sep 1;11(9):727-736. Epub 2018 Aug 1.

g Department of Internal Medicine , American University of Beirut Medical Center , Beirut , Lebanon.

Introduction: Iron deficiency and iron deficiency anemia are highly prevalent among women throughout their lives. Some females are particularly vulnerable to iron deficiency/iron deficiency anemia, including those with heavy menstrual bleeding (HMB) and pregnant/postpartum women. Despite the high prevalence of iron deficiency/iron deficiency anemia in women, the condition is still underdiagnosed and therefore undertreated, with serious clinical consequences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1502081DOI Listing
September 2018
25 Reads

Management and treatment of deep vein thrombosis in special populations.

Expert Rev Hematol 2018 09 25;11(9):685-695. Epub 2018 Jul 25.

a Department of Thrombosis and Hemostasis , Leiden University Medical Center , Leiden , The Netherlands.

Introduction: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most frequent cardiovascular disease besides myocardial infarction and stroke. Because DVT may cause life-threatening conditions, treatment should be started as soon as possible. This comprises certain challenges in special populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1502082DOI Listing
September 2018
2 Reads

Chronic myeloid leukemia and pregnancy: patient and partner perspectives.

Authors:
Marlise R Luskin

Expert Rev Hematol 2018 08 23;11(8):597-599. Epub 2018 Jul 23.

a Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1500889DOI Listing
August 2018
2 Reads

Pacritinib to treat myelofibrosis patients with thrombocytopenia.

Expert Rev Hematol 2018 Sep 19;11(9):707-714. Epub 2018 Jul 19.

a Icahn School of Medicine at Mount Sinai , Tisch Cancer Institute , New York , NY , USA.

Introduction: Treatment with ruxolitinib, a selective JAK1/2 inhibitor, has significantly improved the lives of patients with myelofibrosis. Unfortunately, this treatment is frequently limited by cytopenias, precluding a high-risk group characterized by baseline thrombocytopenia. Additionally, there are no approved treatments for patients who have progressed while receiving ruxolitinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1500456DOI Listing
September 2018
5 Reads